Cefepime safety same as other beta-lactams

The FDA just released a report of a meta-analysis of 88 clinical trials and did not find a difference in all-cause mortality between cefepime and other beta-lactam antibiotics (FDA site). This debunks an earlier meta-analysis of 38 trials that found a higher 30 day all cause mortality in cefepime treated patients compared to other beta-lactam antibiotics.

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment